Bayer AG and Regeneron Pharmaceuticals Inc.’s blockbuster eye drug reached another clinical milestone by showing sustained efficacy in trials that could help the companies push back against a competing product from Roche Holding AG.
Giving 8 milligrams of the drug, Eylea, continued to protect patients from developing vision problems even as they received injections every 16 weeks, Bayer said in a statement on Saturday.
The trials included people suffering from two forms of eye disease that involve blood vessel malfunction. The 8-milligram dosing is being studied in comparison with patients who receive standard 2-milligram doses of Eylea on a more frequent basis.
